| 1 min read
Register for free to listen to this article
Listen with Speechify
0:00
1:00
EDEN PRAIRIE, Minn.—With a final price tag that could surpass $60 million, drug delivery specialist SurModics announced it would acquire Birmingham, Ala.-based Brookwood Pharmaceuticals from the Southern Research Institute, which spun-off the company in 2005 to develop and commercialize biodegradable polymer technology for drug delivery. The company brings with it, 30 service agreements with various pharmaceutical, biotech, and medical device clients.
 
"Our collective technology will allow us to offer both site specific and systemic drug release capabilities to a broader range of customers in several large markets, some of which we do not participate in today," says Bruce Barclay, SurModics president and CEO. "The combination of broader technology platforms and an expanded customer base will help to fulfill several of our strategic objectives, including further diversification of our business."
 
Brookwood will continue as a separate business unit within SurModics and be led by its current president and CEO Dr. Arthur Tipton, who will also become a vice president with SurModics.

About the Author

Related Topics

Loading Next Article...
Loading Next Article...
Subscribe to Newsletter

Subscribe to our eNewsletters

Stay connected with all of the latest from Drug Discovery News.

Subscribe

Sponsored

A person wearing a white lab coat types on a laptop with various overlaid enlarged files shown with plus signs on file folders floating over the laptop screen with a clinical lab shown in the background in grey and white tones.

Enhancing bioanalytical studies with centralized data management

Learn how researchers can improve compliance and efficiency with advanced LIMS solutions.
A 3D-rendered digital illustration of a molecular structure floating among red blood cells in a bloodstream environment.

Explained: How are metabolite biomarkers improving drug discovery and development?

By offering a rich source of insights into disease and drugs, metabolite biomarkers are at the forefront of therapeutic exploration.
Clear cells with round, blue centers are shown against a varied blue background

Supercharging cell line development and engineering with automated single cell sorting

Researchers can enhance efficiency, yield, and consistency in clonal cell line development with specialized tools.
Drug Discovery News March 2025 Issue
Latest IssueVolume 21 • Issue 1 • March 2025

March 2025

March 2025 Issue

Explore this issue